| Position | Action |
|---|---|
| No new capital deployment until Q1 FY27 catalyst or confirmed technical break | Hold existing position only |
| Breakdown below $143.60 on volume >7M | Trim existing position |
| No pre-emptive trim before technical confirmation | Avoid premature sizing adjustments |
PG is a mispriced high-quality cash compounder with a dominant brand moat, expanding margins, and the strategic Thorne acquisition providing wellness market upside at near-52-week-low prices, making the risk/reward asymmetric to the upside for long-term investors.
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 52.60 | neutral |
| MACD | -0.25 | bearish |
| MACD Signal | -0.03 | bearish |
| MACD Histogram | -0.22 | bearish |
| 10 EMA | 146.52 | neutral |
| 50 SMA | 146.56 | neutral |
| 200 SMA | 145.89 | bearish |
| ATR(14) | 3.61 | — |
| Bollinger Upper | 150.28 | — |
| Bollinger Middle | 146.94 | — |
| Bollinger Lower | 143.61 | — |
Support: 145.89 · 143.61 · 142.25 | Resistance: 148.25 · 150.28 · 151.62
PG is in a textbook range-bound regime with compressed moving averages (200 SMA at 145.89, 50 SMA at 146.56, 10 EMA at 146.52 all within a $0.67 band), neutral RSI oscillating in a 43-60 band over the past month, and a fresh bearish MACD crossover with histogram flipped negative to -0.22. Bollinger Bands span 143.61–150.28 with price at the upper-mid (28% of band). ATR has expanded ~22% over six weeks (2.95 to 3.61), signaling volatility is increasing even within the range. Today's +3.04 close (144.97 to 148.01) lacks volume confirmation (7.4M vs. 14.6M on prior high-vol session), suggesting a potential short-covering rally rather than a true reversal. The 200 SMA remains flat-to-slightly declining, confirming no structural uptrend. Key resistance at 150.28/151.62; key support at 145.89/143.61/142.25. The transaction proposal is HOLD pending either a volume-confirmed break above 150.28 or a successful retest of 143.61 as support.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Maintain Hold on PG as prior Underweight calls proved wrong; preserve 3% dividend while awaiting October catalyst with $143.60 stop
Long-term quality thesis remains intact; tactical posture is Hold, not Underweight. PG demonstrates 30% ROE, 4-5% FCF yield, and full-year margin expansion (FY26E 24.3% vs FY25 22.1%). The $1B commodity cost headwind and K-shaped consumer pressure are legitimate risks but signals, not confirmed breakdowns. Three consecutive prior Underweight calls produced compressed or wrong alpha; the support zone at $137-$144 has held multiple times, justifying neutral-weight Hold over continued Underweight. No new capital deployment, no pre-emptive trim, preserve optionality for October catalyst or clearer technical break.
When: October Q1 FY27 earnings release
Then: Mandatory reassessment regardless of price action
Productivity-led margin expansion is the primary growth driver over four years
· concedes: Technical HOLD is a fair call for tactical traders; Q2 revenue missed by 10bps; MACD turned bearish and today's rally was on low volume; Thorne is expensive at $3.8B and near-term dilutive to consensus model; FY27 guidance is cautious; Current ratio under 1.0 and negative tangible book are real metrics (though bull argues misapplied)
PG at $148 with 22x trailing P/E is not a mispriced quality gem but a quality-at-full-price trap; the margin expansion cycle has reversed (Q3 FY26 operating margin fell to 21.6%, below FY22 baseline), revenue growth is volume-negative at +1.5% YoY, the $3.8B Thorne acquisition paid a 60-100% premium to sector comps, and the technical setup shows distribution volume exceeding accumulation, with a fresh bearish MACD crossover warning of further downside.
· concedes: The dividend is real: 65 years of increases, 3% yield, paid through every macro environment; The brand portfolio is durable: Tide, Pampers, Gillette, Crest aren't disappearing, market share is sticky; The cash generation is exceptional: $14-16B annual FCF is real; The balance sheet is investment-grade: Net debt / OCF at 1.4x is comfortable; The Thorne deal is strategically logical: premium wellness is a real adjacency
→ vs conservative: Dividend yield cushion is actually a coupon collected while principal burns — 3% yield cannot offset 10-15% multiple compression when risk-free alternatives yield 4%+
→ vs conservative: 30% ROE is a balance-sheet artifact inflated by buybacks, not a moat — negative tangible book value and 49% goodwill makes the 6.48x price-to-book multiple unjustified
→ vs conservative: Defensive rotation thesis is a fantasy requiring either 25x multiple re-rating with stagnant earnings or $7.50 EPS growth — neither is happening
→ vs neutral: Technical analysis framework is not neutral — MACD bearish crossover, distribution on 14.6M shares, and four upper Bollinger band rejections on declining volume constitute confirmation, not uncertainty
→ vs neutral: Today's +3.04% bounce on only 7.4M shares lacks conviction — it's a short-cover dead cat bounce into the upper band, not a base-building pattern
→ vs neutral: Waiting for more confirmation is letting entry price get worse — the lower Bollinger edge at 143.60 is the path of least resistance, not 167.25
Market Cap
$344.66 B
52-Week High
$167.25
52-Week Low
$137.62
50-Day Avg
$147.33
200-Day Avg
$148.05
Trailing P/E
22.32x
Forward P/E
19.97x
PEG Ratio
5.57
Price / Book
6.48x
EPS (TTM)
$6.63
Forward EPS
$7.41
Dividend Yield
3.01%
Beta
0.377
Revenue FY26E
$84,284 M
Revenue FY25
$84,039 M
Revenue FY24
$82,006 M
Gross Margin (FY26E)
51.2%
Gross Margin (FY25)
51.4%
Gross Margin (FY24)
47.8%
Operating Income FY26E
$20,451 M
Operating Income FY25
$18,545 M
Operating Margin FY26E
24.3%
Operating Margin FY25
22.1%
Net Income FY26E
$15,974 M
Net Income FY25
$14,879 M
Diluted EPS FY26E
$6.62
Diluted EPS FY25
$6.51
Diluted EPS FY24
$6.02
Diluted EPS FY23
$5.90
Diluted Avg Shares
2,422 M
Diluted Avg Shares FY25
2,454 M
Total Assets
$128.4 B
Total Debt
$37.0 B
Net Debt
$24.7 B
Stockholders' Equity
$54.5 B
Net Debt / Equity
0.45x
Current Ratio
0.68
Goodwill & Intangibles
$62.9 B
Operating Cash Flow FY25
$17,817 M
Operating Cash Flow FY24
$19,846 M
Free Cash Flow FY25
$14,044 M
Free Cash Flow FY24
$16,524 M
CapEx FY25
$3,773 M
CapEx FY24
$3,322 M
Dividends Paid FY25
$9,872 M
Dividends Paid FY24
$9,312 M
Buybacks FY25
$6,500 M
Buybacks FY24
$5,006 M
Profit Margin
18.4%
Operating Margin
19.5%
Gross Margin TTM
50.7%
Return on Equity (ROE)
30.3%
Return on Assets (ROA)
10.2%
FCF / Revenue
14.8%
Revenue TTM
$87.03 B
EBITDA TTM
$23.66 B
Net Income TTM
$16.05 B
FCF TTM
$12.84 B
Annual Dividends
~$10 B
Annual Buybacks
$6.5 B
Total Capital Return
~$16 B / yr
Revenue 4-yr CAGR
~1.2%
EPS 3-yr CAGR
~4.0%
Treasury Stock
$142.2 B
FY24 Impairment Charge
$1.34 B
Cash (Mar-26)
$12,306 M
Cash (Mar-25)
$9,116 M
Inventory (Mar-26)
$7,853 M
Inventory Growth YoY
+6%
Q3 FY26 Revenue
$21,235 M
Q3 FY26 Revenue Growth YoY
+7.4%
Q3 FY26 Operating Income
$4,576 M
Q3 FY26 Operating Margin
21.6%
Q3 FY26 Gross Margin
49.5%
Q1 FY26 Operating Margin
26.2%
Q2 FY26 Operating Margin
24.2%
Q2 FY26 Operating Income
$5,366 M
Q3 FY26 Diluted EPS
$1.26
Q2 FY26 Diluted EPS
$1.63
Q1 FY26 Diluted EPS
$1.78
Strengths
Concerns
Procter & Gamble is a high-quality consumer staples conglomerate with an unmatched portfolio of megabrands, demonstrating elite profitability with 30.3% ROE, 19.5% operating margin, and $14-16 B in annual free cash flow generation. The company has grown EPS from $5.90 (FY23) to $6.62 (FY26E) at ~4% CAGR through disciplined margin expansion (22.1% to 24.3%) and share buybacks, while maintaining its Dividend Aristocrat status with 65+ years of consecutive increases at a 3.01% yield. Valuation is full at 22.3x trailing P/E but defensible given the defensive cash flow profile and low 0.377 beta; the trading recommendation is HOLD with bias to BUY on weakness below $140, as the stock consolidates near its 50/200-day moving averages with Q3 FY26 showing encouraging +7.4% YoY revenue acceleration and margin momentum above 24%.